JP2016521567A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521567A5
JP2016521567A5 JP2016518868A JP2016518868A JP2016521567A5 JP 2016521567 A5 JP2016521567 A5 JP 2016521567A5 JP 2016518868 A JP2016518868 A JP 2016518868A JP 2016518868 A JP2016518868 A JP 2016518868A JP 2016521567 A5 JP2016521567 A5 JP 2016521567A5
Authority
JP
Japan
Prior art keywords
sev
genome replication
vector
replication deficient
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016518868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521567A (ja
Filing date
Publication date
Priority claimed from EP13002972.1A external-priority patent/EP2813574B1/en
Application filed filed Critical
Publication of JP2016521567A publication Critical patent/JP2016521567A/ja
Publication of JP2016521567A5 publication Critical patent/JP2016521567A5/ja
Pending legal-status Critical Current

Links

JP2016518868A 2013-06-10 2014-06-10 半生呼吸器合胞体ウイルスワクチン Pending JP2016521567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002972.1 2013-06-10
EP13002972.1A EP2813574B1 (en) 2013-06-10 2013-06-10 Semi-live respiratory syncytial virus vaccine
PCT/EP2014/001576 WO2014198408A1 (en) 2013-06-10 2014-06-10 Semi-live respiratory syncytial virus vaccine

Publications (2)

Publication Number Publication Date
JP2016521567A JP2016521567A (ja) 2016-07-25
JP2016521567A5 true JP2016521567A5 (https=) 2017-07-27

Family

ID=48578770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016518868A Pending JP2016521567A (ja) 2013-06-10 2014-06-10 半生呼吸器合胞体ウイルスワクチン

Country Status (12)

Country Link
US (1) US20160346378A1 (https=)
EP (2) EP2813574B1 (https=)
JP (1) JP2016521567A (https=)
KR (1) KR20160023769A (https=)
CN (1) CN105473724A (https=)
AU (1) AU2014280624A1 (https=)
BR (1) BR112015030742A2 (https=)
CA (1) CA2914826A1 (https=)
EA (1) EA201592299A1 (https=)
HK (1) HK1223643A1 (https=)
MX (1) MX367094B (https=)
WO (1) WO2014198408A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016199936A1 (ja) * 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ2型ウイルスベクター及びワクチン
CN106362144B (zh) * 2016-10-31 2021-02-09 武汉三利生物技术有限公司 呼吸道合胞病毒疫苗
WO2018092887A1 (ja) * 2016-11-17 2018-05-24 国立感染症研究所長が代表する日本国 非感染性パラミクソウイルス粒子を用いた感染症ワクチン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
WO2001092548A2 (en) * 2000-06-01 2001-12-06 St. Jude Children's Research Hospital Vaccine and gene therapy vector and methods of use thereof
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
JP4969444B2 (ja) * 2005-06-14 2012-07-04 ディナベック株式会社 抗体の作製方法

Similar Documents

Publication Publication Date Title
JP2016521566A5 (https=)
JP2017522907A5 (https=)
JP2013501038A5 (https=)
JP2014530010A5 (https=)
JP2014516536A5 (https=)
JP2012530761A5 (https=)
JP2014526883A5 (https=)
JP2017511136A (ja) 腫瘍崩壊ワクシニアウィルス
JP2008529558A5 (https=)
JP2014503206A5 (https=)
CN103442731A (zh) 表达系统
JP2015164424A5 (https=)
JP2014523878A5 (https=)
JP2016513115A5 (https=)
JP2017507181A5 (https=)
JP2014519817A5 (https=)
JP2017502662A5 (https=)
JP2013505017A5 (https=)
JP2018524019A5 (https=)
JP2016513471A5 (https=)
Esposito et al. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline
JP2016521567A5 (https=)
Zhang et al. Advances in protein subunit vaccines against H1N1/09 influenza
JP2016521566A (ja) 半生呼吸器合胞体ウイルスワクチン
Yonemitsu et al. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen